NEW DRUGS IN FIRST LINE: “
DRUG WARS
”
INMUNOTHERAPY VS TKIs
NIVOLUMAB-IPILIMUMAB
CABOZANTINIB
PAZOPANIB
ATEZOLIZUMAB +
BEVACIZUMAB
TIVOZANIB
SUNITINIB